Stockreport

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

ACADIA Pharmaceuticals Inc.  (ACAD) 
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF -- DAYBUE STIX provides Rett syndrome patients and caregivers with new flexibility and choice in their treatment with DAYBUE-- DAYBUE and DAYBUE STIX are the only FDA-ap [Read more]